DSCSA Enforcement: Why Distributors Selling to Small Dispensers Must Act Now

For more than a decade, the Drug Supply Chain Security Act (DSCSA) has reshaped how prescription drugs move through the U.S. supply chain.

Now, the transition period is over, and the consequence for nonadherence includes civil fines of up to $500,000 per violation. For many small businesses, the fine and reputational hit would end operations immediately.

Following years of phased implementation and a stabilization period that ended on November 27, 2024, DSCSA enforcement is active across the pharmaceutical supply chain. For wholesale distributors, enforcement has been in effect since August 27, 2025. For small dispensers, the DSCSA exemption is active until November 27, 2026.

With enforcement in effect and the exemption deadline approaching quickly, it's crucial that distributors can exchange compliant transaction data. Yet despite the industry's long runway to prepare, many distributors continue to face compliance challenges.

According to ColdChainCheck's 2026 compliance tracker, the average compliance score across 1,275 tracked wholesale distributors and third-party logistics providers (3PLs) is 51 out of 100, a rating categorized as "Fair."

The reality is that compliance deadlines have passed, but the compliance gap remains.

DSCSA enforcement: what's required from wholesale distributors

Under DSCSA enforcement, wholesale distributors must be able to:

• Verify product identifiers using serialized package-level data
• Exchange transaction information (TI) and transaction statements (TS) electronically and interoperably using EPCIS (Electronic Product Code Information Services) with every shipment
• Respond to data discrepancies and exceptions within 72 hours
• Provide product tracing documentation within 48 hours of a valid request
• Manage suspect and illegitimate product investigations in real time
• Confirm saleable returns with manufacturers before redistribution
• Trade only with authorized, licensed trading partners

While these requirements may sound straightforward, they can introduce significant operational complexity and compliance issues for distributors when teams use manual or paper-based processes rather than pharmaceutical distribution software.

Summary of all FDA exemptions

The duration of the FDA exemption for DSCSA enforcement varies depending on the eligible trading partners:

• Manufacturers and repackagers were exempt until May 27, 2025
• Wholesale distributors were exempt until August 27, 2025
• Dispensers with 26 or more full-time employees are exempt until November 27, 2026.

The FDA exemption for dispensers ends completely on that date, after which, all dispensers (regardless of size) must:

• Exchange DSCSA data electronically (EPCIS or equivalent)
• Support package-level traceability
• Verify product identifiers (2D barcodes)
• Participate in interoperable data systems
• Fully comply with Section 582(g)(1) requirements  [coldchaincheck.com]

As such, distributors should be transmitting outbound EPCIS files to all customers, including hospitals, clinics, and pharmacies.

Drug distributors who do not currently send EPCIS data under DSCSA because they sell exclusively to small dispensers with under 26 full-time equivalent licensed pharmacists or pharmacy technicians will be required to transmit serialized data electronically (EPCIS or equivalent) to all customers. If they do not, they will not be in compliance with the law when the FDA exemption ends on November 27, 2026.

On the receiving side, dispensers must verify product identifiers against files sent by distributors prior to dispensing drugs to patients. Because of this, it is critical that both dispensers and distributors have the right systems in place so data can flow as needed, ensuring that patients continue to receive life-saving medications.

Bottom line: If you are a distributor without a compliant system in place, you will no longer be able to sell to dispensers when the exemption ends.

The risks of non-compliance

With paper-based systems no longer acceptable, distributors must act now or risk the consequences. The FDA issued 12 warning letters in Q4 2024 to distributors still using paper-based transaction documentation, all citing 21 USC 360eee-1(c)(2). In addition, 5 distributors received enforcement notices for maintaining transaction data in proprietary, non-interoperable formats.

Penalties for non-compliance include civil fines up to $500,000 per violation, potential criminal charges, license revocation, and increased FDA audit frequency.

State-level consequences come into play now as well, with wholesale distributor license renewals in California, Ohio, and Texas requiring DSCSA compliance documentation.

Why the compliance gap persists

Many pharmaceutical distributors understand the regulations but struggle to operationalize them.

As businesses grow, information often becomes fragmented across inventory systems, accounting software, spreadsheets, paper records, and manual workflows.

When traceability data is difficult to access or reporting processes rely heavily on manual effort, compliance becomes difficult to maintain consistently.

The organizations best positioned for long-term compliance have invested in pharmaceutical distribution software to support stronger operational processes, centralized data, and visibility throughout the supply chain.

Preparing for what's next under DSCSA enforcement

For distributors, now is the time to assess whether existing systems and processes can support ongoing compliance requirements.

Key questions to consider include:

• Can your team quickly access transaction and inventory records when needed?
• Do you have reliable lot-level traceability throughout your operation?
• Are compliance-related reports easy to generate?
• Is critical data centralized or spread across multiple systems?
• Are manual processes creating unnecessary risk?

The answers can help identify potential gaps before they become larger operational or regulatory challenges.

Closing the compliance gap

As DSCSA enforcement moves from preparation to ongoing accountability, pharmaceutical distributors must maintain accurate records, prioritize traceability, and quickly respond to compliance-related requests.

For SMB distributors, the aim should be to create operational processes that support both compliance and long-term growth.

In addition, distributors who are selling exclusively to small dispensers and not yet transmitting serialized data electronically must act before the exemption ends in November 2026 to remain compliant with the law.

Blue Link pharmaceutical distribution software can help your organization close the compliance gap without the cost or complexity of enterprise ERP solutions.

We offer:

• Automated lot tracking with full lot-level traceability throughout the supply chain
• Audit trail and reporting built into the core system, not bolted on
• Centralized transaction data across inventory, orders, and warehouse in a single database
• Support for compliance in regulated distribution environments (FDA, DEA, Health Canada)

With these features, your organization can approach compliance with confidence, all while strengthening operational efficiency and reducing manual work.

As DSCSA enforcement continues, distributors that invest in visibility, traceability, and operational efficiency will be positioned to navigate regulatory requirements and future growth with confidence. If you do not currently have the needed systems in place, act now so you remain compliant and able to continue selling to all of your customers.

Ready to learn how Blue Link helps wholesale distributors maintain regulatory compliance with robust accounting and inventory management features?

Download our free PDF here, or book a time to speak with our team.

References

1. ColdChainCheck: Ups and Downs in the March to DSCSA Compliance (Feb 2026)
2. Pharmaceutical Commerce (Apr 2026)
3. DrugZone: New FDA and DSCSA Compliance Requirements U.S. Drug Distributors Must Follow in 2026 (Jan 2026)
4. FDA.gov: Section 582 FD&C Act requirements